Semaglutide vs Retatrutide.
Side-by-side research comparison of Semaglutide and Retatrutide: dosing, half-life, side effects, and mechanism of action.
Quick Verdict
Retatrutide for maximum weight loss in advanced obesity (≥24% body weight in Phase 2). Semaglutide for a proven, globally available, cardiovascular-safe starting point. Tirzepatide sits between them as the current FDA-approved sweet spot.
Side-by-Side Analysis
| Dimension | Semaglutide | Retatrutide |
|---|---|---|
| Mechanism | GLP-1 receptor agonism mimics the incretin hormone to reduce appetite, slow gastric emptying, improve insulin sensitivity, and provide cardiovascular protection. | Multi-receptor activation for appetite suppression, fat oxidation, energy expenditure. |
| Primary Benefits | Fat loss, appetite control, cardiovascular benefits | Superior body recomposition, massive fat loss, metabolic health |
| Typical Dose | 250–250mcg | 2000–2000mcg |
| Route | SubQ | SubQ |
| Frequency | 1x/wk | 1x/wk |
| Half-Life | 168 hours | 144 hours |
| FDA Status | Approved | Approved |
| Evidence Grade | very-strong | strong |
| Key Studies | 20+ indexed | 20+ indexed |
| Lowest Price | $47.99 / 5mg via Amino Club | $69.99 / 10mg via Amino Club |
Which one should you choose?
Who Should Choose Semaglutide?
Choose Semaglutide if you:
- Are starting a GLP-1 protocol for the first time and want maximum safety data
- Have established cardiovascular disease (SELECT trial evidence)
- Cost or insurance coverage is a limiting factor
- Need a globally available, prescription-accessible option
Who Should Choose Retatrutide?
Choose Retatrutide if you:
- Have severe obesity (BMI >40) that has not responded to dual agonists
- Want to study glucagon-driven thermogenesis in combination with GLP-1/GIP
- Are comfortable with Phase 2 research-stage compounds without Phase 3 approval
- Are targeting MASLD (metabolic liver disease) alongside weight loss
Can you stack Semaglutide + Retatrutide?
Do NOT stack Semaglutide and Retatrutide — they share the GLP-1 receptor. Concurrent use creates dangerous additive stimulation with compounded GI toxicity and hypoglycemia risk. Use one GLP-1-class agent at a time.
Vendor Pricing
· Affiliate links · Prices verified 2026Semaglutide
2 vendorsRetatrutide
1 vendorAffiliate disclosure: PeptiDex may earn a commission from purchases via vendor links at no extra cost to you. See our methodology.
Frequently Asked Questions
Phase 2 Retatrutide data shows ~24% body weight loss at 24 weeks vs Semaglutide's ~15% at max dose (STEP 1, 68 weeks). Retatrutide is not yet Phase 3 approved; Semaglutide is FDA-approved and widely available.
Related Comparisons
Deep Dive Profiles
Research Tools
Research Use Only — Not Medical Advice
This comparison is provided for educational and research purposes only. It does not constitute medical, prescribing, or treatment advice. Clinical data cited here is sourced from published peer-reviewed trials and FDA labels. Consult a qualified healthcare professional before making any decisions about medications or research compounds. PeptiDex is an informational resource and does not sell pharmaceutical products.